Please login to the form below

Not currently logged in
Email:
Password:

Cedila Therapeutics

This page shows the latest Cedila Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    1 trial of its lead candidate ARV-110 in prostate cancer earlier this year, ahead of rival biotechs such as C4 Therapeutics and Kymera Therapeutics as well as big pharma firms ... Other approaches are also in early-stage testing. Deubiquitylating (DUB)

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...